Anticalins: An emerging class of novel biologics to treat cancer and other severe diseases

Drugs of the Future

Volumn 38, Issue 3, 2013, Pages 169-179

  Mendler, C T ^a,b   Skerra, A ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Biopharmaceutical; Lipocalin; Protein engineering; Protein therapeutic; Tumor therapy

Indexed keywords

ALPHA 1 MICROGLOBULIN; ANGIOCAL; ANTICALIN DERIVATIVE; APOLIPOPROTEIN D; BEVACIZUMAB; BILIN BINDING PROTEIN; BINDING PROTEIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DIGOXIGENIN; ECULIZUMAB; FIBRONECTIN; FLUORESCEIN; HEPCIDIN; HYBRID PROTEIN; IPILIMUMAB; LIPOCALIN; LIPOCALIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; ODORANT BINDING PROTEIN; OROSOMUCOID; PLACENTA PROTEIN 14; PRS 010; PRS 050; PRS 080; PSEUDOMONAS EXOTOXIN; RETINOL BINDING PROTEIN; REV 576; SIDEROCALIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN A;

ADVANCED CANCER; AUTOIMMUNE DISEASE; BLEEDING; BREAST CANCER; CANCER IMMUNOTHERAPY; COLORECTAL CANCER; DRUG BINDING SITE; DRUG CONJUGATION; DRUG DOSE ESCALATION; DRUG PENETRATION; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; GLIOMA; HUMAN; HYPERTENSION; METASTATIC MELANOMA; MOLECULAR RECOGNITION; MOLECULAR SIZE; MUTAGENESIS; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PHAGE DISPLAY; PROTEIN DOMAIN; PROTEIN ENGINEERING; PROTEIN FUNCTION; REVIEW; SOLID TUMOR; THROMBOCYTOPENIA; WOUND HEALING IMPAIRMENT;

EID: 84930541904     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2013.038.03.1931054     Document Type: Review

References (107)

1. Akerstrom, B., Borregaard, N., Flower, D.A., Salier, J.-S. Lipocalins. Landes Bioscience: Georgetown, Texas 2006.
2. Flower, D.R. Multiple molecular recognition properties of the lipocalin protein family. J Mol Recognit 1995, 8(3): 185-95.
3. Breustedt, D.A., Schönfeld, D.L., Skerra, A. Comparative ligand-binding analysis of ten human lipocalins. Biochim Biophys Acta 2006, 1764(2): 161-73.
4. Skerra, A. Anticalins as alternative binding proteins for therapeutic use. Curr Opin Mol Ther 2007, 9(4): 336-44. (Pubitemid 47255666)
5. Cowan, S.W., Newcomer, M.E., Jones, T.A. Crystallographic refinement of human serum retinol binding protein at 2Å resolution. Proteins 1990, 8(1): 44-61. (Pubitemid 20235331)
6. Newcomer, M.E., Jones, T.A., Aqvist, J., Sundelin, J., Eriksson, U., Rask, L., Peterson, P.A. The three-dimensional structure of retinol-binding protein. EMBO J 1984, 3(7): 1451-4.
7. Flower, D.R. The lipocalin protein family: Structure and function. Biochem J 1996, 318(Pt. 1): 1-14. (Pubitemid 26283618)
8. Skerra, A. Lipocalins as a scaffold. Biochim Biophys Acta 2000, 1482(1-2): 337-50.
9. Holliger, P., Hudson, P.J. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005, 23(9): 1126-36. (Pubitemid 41486394)
10. Schlehuber, S., Skerra, A. Lipocalins in drug discovery: From natural ligandbinding proteins to "anticalins". Drug Discov Today 2005, 10(1): 23-33. (Pubitemid 40164816)
11. Veronese, F.M. PEGylated Protein Drugs: Basic Science and Clinical Applications. Birkhäuser Verlag: Basel 2009.
12. Goetz, D.H., Holmes, M.A., Borregaard, N., Bluhm, M.E., Raymond, K.N., Strong, R.K. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell 2002, 10(5): 1033-43. (Pubitemid 36001971)
13. Holmes, M.A., Paulsene, W., Jide, X., Ratledge, C., Strong, R.K. Siderocalin (Lcn 2) also binds carboxymycobactins, potentially defending against mycobacterial infections through iron sequestration. Structure 2005, 13(1): 29-41. (Pubitemid 40092472)
14. Flo, T.H., Smith, K.D., Sato, S. et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 2004, 432(7019): 917-21. (Pubitemid 40037155)
15. Schalk, I.J., Guillon, L. Pyoverdine biosynthesis and secretion in Pseudomonas aeruginosa: Implications for metal homeostasis. Environ Microbiol 2012, Epub ahead of print.
16. Hotta, K., Kim, C.Y., Fox, D.T., Koppisch, A.T. Siderophore-mediated iron acquisition in Bacillus anthracis and related strains. Microbiology 2010, 156(Pt. 7): 1918-25.
17. Muller, S.I., Valdebenito, M., Hantke, K. Salmochelin, the long-overlooked catecholate siderophore of Salmonella. Biometals 2009, 22(4): 691-5.
18. Russell, L.M., Cryz, S.J. Jr., Holmes, R.K. Genetic and biochemical evidence for a siderophore-dependent iron transport system in Corynebacterium diphtheriae. Infect Immun 1984, 45(1): 143-9. (Pubitemid 14078931)
19. Schmidt-Ott, K.M., Mori, K., Kalandadze, A. et al. Neutrophil gelatinaseassociated lipocalin-mediated iron traffic in kidney epithelia. Curr Opin Nephrol Hypertens 2006, 15(4): 442-9. (Pubitemid 44297988)
20. Mori, K., Lee, H.T., Rapoport, D. et al. Endocytic delivery of lipocalinsiderophore- iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 2005, 115(3): 610-21. (Pubitemid 40322235)
21. Breustedt, D.A., Korndörfer, I.P., Redl, B., Skerra, A. The 1.8-Å crystal structure of human tear lipocalin reveals an extended branched cavity with capacity for multiple ligands. J Biol Chem 2005, 280(1): 484-93. (Pubitemid 40165013)
22. Fluckinger, M., Haas, H., Merschak, P., Glasgow, B.J., Redl, B. Human tear lipocalin exhibits antimicrobial activity by scavenging microbial siderophores. Antimicrob Agents Chemother 2004, 48(9): 3367-72. (Pubitemid 39129332)
23. Skerra, A. 'Anticalins': A new class of engineered ligand-binding proteins with antibody-like properties. J Biotechnol 2001, 74(4): 257-75. (Pubitemid 34186236)
24. Balogh, P., Szekeres, G., Nemeth, P. Hapten-mediated identification of cell membrane antigens using an anti-FITC monoclonal antibody. J Immunol Methods 1994, 169(1): 35-40. (Pubitemid 24084584)
25. McCreery, T. Digoxigenin labeling. Mol Biotechnol 1997, 7(2): 121-4. (Pubitemid 127499100)
26. Eyer, F., Steimer, W., Nitzsche, T. et al. Intravenous application of an anticalin dramatically lowers plasma digoxin levels and reduces its toxic effects in rats. Toxicol Appl Pharmacol 2012, 263(3): 352-9.
27. Schmidt, F.S., Skerra, A. The bilin-binding protein of Pieris brassicae. cDNA sequence and regulation of expression reveal distinct features of this insect pigment protein. Eur J Biochem 1994, 219(3): 855-63. (Pubitemid 24050955)
28. Huber, R., Schneider, M., Mayr, I. et al. Molecular structure of the bilin binding protein (BBP) from Pieris brassicae after refinement at 2.0 Å resolution. J Mol Biol 1987, 198(3): 499-513.
29. Beste, G., Schmidt, F.S., Stibora, T., Skerra, A. Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold. Proc Natl Acad Sci U S A 1999, 96(5): 1898-903. (Pubitemid 29117839)
30. Schlehuber, S., Beste, G., Skerra, A. A novel type of receptor protein, based on the lipocalin scaffold, with specificity for digoxigenin. J Mol Biol 2000, 297(5): 1105-20.
31. Korndörfer, I.P., Beste, G., Skerra, A. Crystallographic analysis of an "anticalin" with tailored specificity for fluorescein reveals high structural plasticity of the lipocalin loop region. Proteins 2003, 53(1): 121-9. (Pubitemid 37059550)
32. Korndörfer, I.P., Schlehuber, S., Skerra, A. Structural mechanism of specific ligand recognition by a lipocalin tailored for the complexation of digoxigenin. J Mol Biol 2003, 330(2): 385-96. (Pubitemid 36773710)
33. Vopel, S., Mühlbach, H., Skerra, A. Rational engineering of a fluoresceinbinding anticalin for improved ligand affinity. Biol Chem 2005, 386(11): 1097-104. (Pubitemid 41705364)
34. Kim, H.J., Eichinger, A., Skerra, A. High-affinity recognition of lanthanide(III) chelate complexes by a reprogrammed human lipocalin 2. J Am Chem Soc 2009, 131(10): 3565-76.
35. Vogt, M., Skerra, A. Construction of an artificial receptor protein ("anticalin") based on the human apolipoprotein D. ChemBioChem 2004, 5(2): 191-9. (Pubitemid 39268783)
36. Breustedt, D.A., Chatwell, L., Skerra, A. A new crystal form of human tear lipocalin reveals high flexibility in the loop region and induced fit in the ligand cavity. Acta Crystallogr D Biol Crystallogr 2009, 65(Pt. 10): 1118-25.
37. Schönfeld, D., Matschiner, G., Chatwell, L. et al. An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies. Proc Natl Acad Sci U S A 2009, 106(20): 8198-203.
38. Gebauer, M., Schiefner, A., Matschiner, G., Skerra, A. Combinatorial design of an anticalin directed against the extra-domain B for the specific targeting of oncofetal fibronectin. J Mol Biol 2013, 425(4): 780-802.
39. Ferrara, N., Hillan, K.J., Gerber, H.P., Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004, 3(5): 391-400. (Pubitemid 38618122)
40. Skerra, A. Imitating the humoral immune response. Curr Opin Chem Biol 2003, 7(6): 683-93. (Pubitemid 37486111)
41. Van den Brulle, J., Fischer, M., Langmann, T. et al. A novel solid phase technology for high-throughput gene synthesis. Biotechniques 2008, 45(3): 340-3.
42. Gebauer, M., Skerra, A. Anticalins: Small engineered binding proteins based on the lipocalin scaffold. Methods Enzymol 2012, 503: 157-88.
43. Gebauer, M., Skerra, A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 2009, 13(3): 245-55.
44. Schlehuber, S., Skerra, A. Tuning ligand affinity, specificity, and folding stability of an engineered lipocalin variant - a so-called 'anticalin' - using a molecular random approach. Biophys Chem 2002, 96(2-3): 213-28. (Pubitemid 34548234)
45. Schlehuber, S., Skerra, A. Duocalins: Engineered ligand-binding proteins with dual specificity derived from the lipocalin fold. Biol Chem 2001, 382(9): 1335-42. (Pubitemid 32976493)
46. Paesen, G.C., Adams, P.L., Harlos, K., Nuttall, P.A., Stuart, D.I. Tick histamine- binding proteins: Isolation, cloning, and three-dimensional structure. Mol Cell 1999, 3(5): 661-71.
47. Fredslund, F., Laursen, N.S., Roversi, P. et al. Structure of and influence of a tick complement inhibitor on human complement component 5. Nat Immunol 2008, 9(7): 753-60. (Pubitemid 351859158)
48. Couillin, I., Maillet, I., Vargaftig, B.B. et al. Arthropod-derived histaminebinding protein prevents murine allergic asthma. J Immunol 2004, 173(5): 3281-6. (Pubitemid 39142036)
49. Barratt-Due, A., Thorgersen, E.B., Lindstad, J.K. et al. Ornithodoros moubata complement inhibitor is an equally effective C5 inhibitor in pigs and humans. J Immunol 2011, 187(9): 4913-9.
50. Hepburn, N.J., Williams, A.S., Nunn, M.A., Chamberlain-Banoub, J.C., Hamer, J., Morgan, B.P., Harris, C.L. In vivo characterization and therapeutic efficacy of a C5-specific inhibitor from the soft tick Ornithodoros moubata. J Biol Chem 2007, 282(11): 8292-9. (Pubitemid 47093564)
51. Keating, G.M., Lyseng-Williamson, K.A., McKeage, K. Eculizumab: A guide to its use in paroxysmal nocturnal hemoglobinuria. BioDrugs 2012, 26(2): 125-30.
52. Soltys, J., Kusner, L.L., Young, A. et al. Novel complement inhibitor limits severity of experimentally myasthenia gravis. Ann Neurol 2009, 65(1): 67-75.
53. Halstead, S.K., Humphreys, P.D., Zitman, F.M., Hamer, J., Plomp, J.J., Willison, H.J. C5 inhibitor rEV576 protects against neural injury in an in vitro mouse model of Miller Fisher syndrome. J Peripher Nerv Syst 2008, 13(3): 228-35.
54. Mross, K., Fischer, R., Richly, H. et al. First in human phase I study of PRS- 050 (Angiocal), a VEGF-A targeting anticalin, in patients with advanced solid tumors: Results of a dose escalation study. Mol Cancer Ther 2011, 10(11, Suppl.): A212.
55. Ward, D.M., Kaplan, J. Ferroportin-mediated iron transport: Expression and regulation. Biochim Biophys Acta 2012, 1823(9): 1426-33.
56. Atkinson, M.A., White, C.T. Hepcidin in anemia of chronic kidney disease: review for the pediatric nephrologist. Pediatr Nephrol 2012, 27(1): 33-40.
57. Olafsen, T. Fc engineering: Serum half-life modulation through FcRn binding. Methods Mol Biol 2012, 907: 537-56.
58. Binder, U., Skerra, A. Half-life extension of therapeutic proteins via genetic fusion to recombinant PEG mimetics. In: Therapeutic Proteins - Strategies to Modulate Their Plasma Half-lives. R. Kontermann (Ed.). Wiley-VCH: Weinheim 2012, 63-80.
59. Ferrara, N., Gerber, H.P., LeCouter, J. The biology of VEGF and its receptors. Nat Med 2003, 9(6): 669-76. (Pubitemid 36749215)
60. Ausprunk, D.H., Folkman, J. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res 1977, 14(1): 53-65. (Pubitemid 8153798)
61. Hahnfeldt, P., Panigrahy, D., Folkman, J., Hlatky, L. Tumor development under angiogenic signaling: A dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res 1999, 59(19): 4770-5. (Pubitemid 29472873)
62. Folkman, J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971, 285(21): 1182-6.
63. Muhsin, M., Graham, J., Kirkpatrick, P. Bevacizumab. Nat Rev Drug Discov 2004, 3(12): 995-6. (Pubitemid 39642357)
64. Chekhonin, V.P., Shein, S.A., Korchagina, A.A., Gurina, O.I. VEGF in tumor progression and targeted therapy. Curr Cancer Drug Targets 2013, Epub ahead of print.
65. Kumar, J., Bhargava, M., Aggarwal, S. Bevacizumab-induced reversible thrombocytopenia in a patient with adenocarcinoma of colon: Rare adverse effect of bevacizumab. Case Rep Oncol Med 2012, 2012: 695430.
66. Leal, T., Robins, H.I. Bevacizumab induced reversible thrombocytopenia in a patient with recurrent high-grade glioma: A case report. Cancer Chemother Pharmacol 2010, 65(2): 399-401.
67. Meyer, T., Robles-Carrillo, L., Robson, T. et al. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost 2009, 7(1): 171-81.
68. Hurwitz, H.I., Fehrenbacher, L., Hainsworth, J.D. et al. Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for firstline metastatic colorectal cancer. J Clin Oncol 2005, 23(15): 3502-8.
69. Castellani, P., Viale, G., Dorcaratto, A., Nicolo, G., Kaczmarek, J., Querze, G., Zardi, L. The fibronectin isoform containing the ED-B oncofetal domain: A marker of angiogenesis. Int J Cancer 1994, 59(5): 612-8. (Pubitemid 24358583)
70. Pujuguet, P., Hammann, A., Moutet, M., Samuel, J.L., Martin, F., Martin, M. Expression of fibronectin ED-A+ and ED-B+ isoforms by human and experimental colorectal cancer. Contribution of cancer cells and tumorassociated myofibroblasts. Am J Pathol 1996, 148(2): 579-92.
71. Johannsen, M., Spitaleri, G., Curigliano, G. et al. The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer 2010, 46(16): 2926-35.
72. Sauer, S., Erba, P.A., Petrini, M. et al. Expression of the oncofetal ED-Bcontaining fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 2009, 113(10): 2265-74.
73. Lipson, E.J., Drake, C.G. Ipilimumab: An anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 2011, 17(22): 6958-62.
74. Leach, D.R., Krummel, M.F., Allison, J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996, 271(5256): 1734-6. (Pubitemid 26102823)
75. Wurch, T., Pierre, A., Depil, S. Novel protein scaffolds as emerging therapeutic proteins: From discovery to clinical proof-of-concept. Trends Biotechnol 2012, 30(11): 575-82.
76. Pastan, I. Immunotoxins containing Pseudomonas exotoxin A: A short history. Cancer Immunol Immunother 2003, 52(5): 338-41. (Pubitemid 36578027)
77. Palmisano, G.L., Tazzari, P.L., Cozzi, E. et al. Expression of CTLA-4 in nonhuman primate lymphocytes and its use as a potential target for specific immunotoxin-mediated apoptosis: Results of in vitro studies. Clin Exp Immunol 2004, 135(2): 259-66. (Pubitemid 38177965)
78. Schrama, D., Reisfeld, R.A., Becker, J.C. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 2006, 5(2): 147-59.
79. Wu, A.M., Senter, P.D. Arming antibodies: Prospects and challenges for immunoconjugates. Nat Biotechnol 2005, 23(9): 1137-46. (Pubitemid 41486395)
80. Li, Z., Qu, Y., Li, H., Yuan, J. Truncations of gelonin lead to a reduction in its cytotoxicity. Toxicology 2007, 231(2-3): 129-36. (Pubitemid 46283156)
81. Cao, Y., Marks, J.D., Marks, J.W., Cheung, L.H., Kim, S., Rosenblum, M.G. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: In vitro and in vivo studies. Cancer Res 2009, 69(23): 8987-95.
82. Weiden, P.L., Breitz, H.B., Press, O. et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): Initial phase I/II study results. Cancer Biother Radiopharm 2000, 15(1): 15-29. (Pubitemid 30108614)
83. Carrico, I.S., Carlson, B.L., Bertozzi, C.R. Introducing genetically encoded aldehydes into proteins. Nat Chem Biol 2007, 3(6): 321-2. (Pubitemid 46789266)
84. Hochepied, T., Berger, F.G., Baumann, H., Libert, C. α 1-acid glycoprotein: An acute phase protein with inflammatory and immunomodulating properties. Cytokine Growth Factor Rev 2003, 14(1): 25-34. (Pubitemid 36098429)
85. Israili, Z.H., Dayton, P.G. Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab Rev 2001, 33(2): 161-235. (Pubitemid 32703255)
86. Fournier, T., Medjoubi, N.N., Porquet, D. Alpha-1-acid glycoprotein. Biochim Biophys Acta 2000, 1482(1-2): 157-71.
87. Routledge, P.A. Clinical relevance of alpha 1 acid glycoprotein in health and disease. Prog Clin Biol Res 1989, 300: 185-98.
88. Schönfeld, D.L., Ravelli, R.B., Mueller, U., Skerra, A. The 1.8-Å crystal structure of α 1-acid glycoprotein (Orosomucoid) solved by UV RIP reveals the broad drug-binding activity of this human plasma lipocalin. J Mol Biol 2008, 384(2): 393-405.
89. Larsson, J., Allhorn, M., Kerstrom, B. The lipocalin alpha(1)- microglobulin binds heme in different species. Arch Biochem Biophys 2004, 432(2): 196- 204. (Pubitemid 39470016)
90. Meining, W., Skerra, A. The crystal structure of human α 1-microglobulin reveals a potential haem-binding site. Biochem J 2012, 445(2): 175-82.
91. Akerstrom, B., Lögdberg, L., Berggård, T., Osmark, P., Lindqvist, A. α1- Microglobulin: A yellow-brown lipocalin. Biochim Biophys Acta 2000, 1482(1-2): 172-84.
92. Dilley, W.G., Haagensen, D.E., Cox, C.E., Wells, S.A. Jr. Immunologic and steroid binding properties of the GCDFP-24 protein isolated from human breast gross cystic disease fluid. Breast Cancer Res Treat 1990, 16(3): 253-60.
93. Eichinger, A., Nasreen, A., Kim, H.J., Skerra, A. Structural insight into the dual ligand specificity and mode of high density lipoprotein association of apolipoprotein D. J Biol Chem 2007, 282(42): 31068-75. (Pubitemid 350035183)
94. Rassart, E., Bedirian, A., Do Carmo, S., Guinard, O., Sirois, J., Terrisse, L., Milne, R. Apolipoprotein D. Biochim Biophys Acta 2000, 1482(1-2): 185- 98.
95. Seppala, M., Taylor, R.N., Koistinen, H., Koistinen, R., Milgrom, E. Glycodelin: A major lipocalin protein of the reproductive axis with diverse actions in cell recognition and differentiation. Endocr Rev 2002, 23(4): 401-30. (Pubitemid 34925639)
96. Halttunen, M., Kamarainen, M., Koistinen, H. Glycodelin: A reproductionrelated lipocalin. Biochim Biophys Acta 2000, 1482(1-2): 149-56.
97. Kjeldsen, L., Cowland, J.B., Borregaard, N. Human neutrophil gelatinaseassociated lipocalin and homologous proteins in rat and mouse. Biochim Biophys Acta 2000, 1482(1-2): 272-83.
98. Miethke, M., Skerra, A. Neutrophil gelatinase-associated lipocalin expresses antimicrobial activity by interfering with L-norepinephrine-mediated bacterial iron acquisition. Antimicrob Agents Chemother 2010, 54(4): 1580-9.
99. Briand, L., Eloit, C., Nespoulous, C. et al. Evidence of an odorant-binding protein in the human olfactory mucus: Location, structural characterization, and odorant-binding properties. Biochemistry 2002, 41(23): 7241-52. (Pubitemid 34602440)
100. .Tegoni, M., Pelosi, P., Vincent, F. et al. Mammalian odorant binding proteins. Biochim Biophys Acta 2000, 1482(1-2): 229-40.
101. Bianchet, M.A., Bains, G., Pelosi, P., Pevsner, J., Snyder, S.H., Monaco, H.L., Amzel, L.M. The three-dimensional structure of bovine odorant binding protein and its mechanism of odor recognition. Nat Struct Biol 1996, 3(11): 934-9. (Pubitemid 26398326)
102. .Newcomer, M.E., Ong, D.E. Plasma retinol binding protein: Structure and function of the prototypic lipocalin. Biochim Biophys Acta 2000, 1482(1- 2): 57-64.
103. .Kanai, M., Raz, A., Goodman, D.S. Retinol-binding protein: The transport protein for vitamin A in human plasma. J Clin Invest 1968, 47(9): 2025-44.
104. .Glasgow, B.J., Abduragimov, A.R., Farahbakhsh, Z.T., Faull, K.F., Hubbell, W.L. Tear lipocalins bind a broad array of lipid ligands. Curr Eye Res 1995, 14(5): 363-72.
105. .Redl, B. Human tear lipocalin. Biochim Biophys Acta 2000, 1482(1-2): 241-8.
106. .Steiner, M., Gutbrodt, K.L., Krall, N., Neri, D. Tumor-targeting antibodyanticalin fusion proteins for in vivo pretargeting applications. Bioconjug Chem 2013, 24(2): 234-41.
107. Egen, J.G., Kuhns, M.S., Allison, J.P. CTLA-4: New insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002, 3(7): 611-8. (Pubitemid 34752469)